Table 4 Main procedure outcomes (Intention-To-Treat and Per-Protocol analysis).

From: Efficacy of a newly developed guidewire for selective biliary access

N (%)

Experimental (n = 191)

Control (n = 185)

Difference in proportion (%)(two-sided 95% CI)

P-value†

P-value‡

Technical success of primary WGC

151 (79.1)

131 (70.8)

8.25 (− 0.48–16.98)

 < .001

0.064

Technical success including cross-over

156 (81.7)

126 (68.1)

13.57% (4.90–22.24)

 < .001

0.002

Technical success of primary WGC (PP)

151/153 (98.7)

131/132 (99.2)

− 0.55% (− 2.88–1.78)

 < .001

1.000

Technical success including cross-over (PP)

152 (99.3)

130 (98.5)

0.86% (− 1.58–3.31)

 < .001

0.597

Overcoming methods in difficult cannulation

 Precut fistulotomy

22 (11.5)

32 (17.3)

  

0.110

 Double-guidewire cannulation

1 (0.5)

3 (1.6)

  

0.365

 Biliary access after PD

16 (8.4)

23 (12.4)

  

0.197

Overall cannulation success

186 (97.4)

181 (97.8)

− 0.46 (− 3.54–2.63)

 < .0001

1.000

Cannulation method

    

0.908

 Conventional cannula

65 (34)

64 (34.6)

   

 Papillotome

126 (66)

121 (65.4)

   

Frequency of papillary contacts, median (IQR) [range]

2 (1–4) [1, 20]

2 (1–4) [1, 16]

  

0.240

Cannulation time°, median (IQR) [range]

53 (22–180) [3, 1506]

77 (30–240) [1, 2848]

  

0.047

Cannulation time°, median (IQR) [range] (PP)

42 (20–115) [3, 400]

45 (23–115) [1, 833]

  

0.446

Total procedure time*, median (IQR) [range]

545 (360–927) [120, 3610]

562 (400–900) [180, 3514]

  

0.420

GW looping during cannulation

    

0.244

 None

125 (65.4)

131 (70.8)

   

 in CBD

66 (34.6)

53 (28.6)

   

 in PD

0

1 (0.5)

   

GW type

Straight

Angled

Straight

Angled

  

0.868

78 (40.8)

113 (59.2)

74 (40)

110 (60)

   

 Technical success of primary WGC

65 (83.3)

86 (76.1)

56 (75.7)

75 (67.6)

  

0.100

 DBC, difficult biliary cannulation

24 (30.8)

42 (37.2)

36 (48.6)

57 (51.4)

  

0.015

  1. WGC, wire-guided cannulation; CBD, common bile duct; PD, pancreatic duct; GW, guidewire; PP, per protocol analysis; IQR, interquartile range.
  2. From ampulla of Vater access to CBD access.
  3. *From ampulla of Vater access to completion of procedure.
  4.  P-value for non-inferiority test using z-statistics with non-inferiority margin of 15%.
  5.  P-value by Pearson chi-square test, Fisher's exact test, or Wilcoxon rank sum test as appropriate.